| | Business Summary | | Medarex,
Inc.
is
a
human
monoclonal
antibody-based
company
with
integrated
discovery,
development
and
clinical
supply
manufacturing
capabilities.
The
Company
is
able
to
create
fully
human
monoclonal
antibodies
using
its
UltiMAb
Human
Antibody
Development
System.
This
unique
combination
of
human
antibody
technologies
includes
HuMAb-Mouse,
in
which
the
mouse
genes
for
creating
antibodies
have
been
inactivated
and
replaced
by
human
antibody
genes;
TC
Mouse
(pursuant
to
an
agreement
with
Kirin
Brewery
Co.
Ltd),
which
is
transchromosomic,
meaning
that
100%
of
the
human
antibody
genes
contained
in
the
transplanted
chromosomes
are
present
in
the
mouse;
and
a
crossbred
mouse
that
combines
the
traits
of
the
Company's
HuMAb-Mouse
with
Kirin's
TC
Mouse.
With
its
UltiMAb
Human
Antibody
Development
System,
the
Company
believes
it
has
assembled
a
platform
of
mice
for
creating
the
entire
spectrum
of
fully
human
antibodies,
which
typically
have
high
affinity. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Medarex
is
a
human
monoclonal
antibody-based
company
with
integrated
discovery,
development
and
manufacturing
capabilities,
utilizing
the
Company's
genetically
engineered
mice
to
create
fully
human
monoclonal
antibodies.
For
the
six
months
ended
6/30/01,
revenues
totalled
$17.1
million,
up
from
$5.2
million.
Net
income
totalled
$7.6
million
vs.
a
loss
of
$9.9
million.
Results
reflect
increased
license
revenues,
and
increased
interest
income. | | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Irwin Lerner, 69
Chairman | -- | -- | Donald Drakeman, Ph.D., 45
Pres,
CEO, | $1.1M | $2.0M | Michael Appelbaum, 53
Exec.
VP-Fin., Director | 992K | 2.9M | Christian Schade
Sr.
VP, CFO | -- | -- | Randall Curnow, M.D., 56
CMO
and Sr. VP | 424K | 131K | | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/m/medx.gif)